Samsung Biologics announced on April 26, 2021 that it has expanded its 2018 contract manufacturing deal with TG Therapeutics, a US based healthcare company, for the supply of TG’s ublituximab, an investigational anti-CD20 monoclonal antibody (mAb).
Since the start of the collaboration, TG has completed a rolling submission of a biologics license application to FDA requesting approval of ublituximab, in combination with ukoniqtm (umbralisib), TG’s oral once-daily inhibitor of PI3K-delta and CK1-epsilon for the treatment of chronic lymphocytic leukemia, Samsung said in a company press release. The mAb was also involved in two successful Phase III clinical trials directed at patients with relapsing forms of multiple sclerosis (MS).
